Amazon's March 31, 2026 Supplement Claims Deadline: What Sellers Must Fix Now

Amazon has spent 2026 tightening enforcement on dietary supplements, and the sharpest edge so far is a deadline: as of March 31, 2026, listings that carry misleading ingredient claims are subject to deactivation. Industry reporting on the seller notifications, including coverage of the March deadline, describes the target clearly. Amazon is going after detail pages whose ingredient amounts do not match the product's own Supplement Facts panel.

If you sell supplements on Amazon and have not audited your catalog against your labels since the policy took effect, this article is your checklist. The deadline has passed, but enforcement is ongoing, and most sellers who get hit now are hit for copy written years ago.

What Amazon is actually enforcing

The policy sounds simple: every ingredient claim on a product detail page must match the Supplement Facts panel in name, amount, and presentation. In practice, three patterns account for most of the flagged listings.

1. Inflated extract weights

This is the practice the policy was written to stop. A product contains 500 mg of a 10:1 ashwagandha extract, and the bullets advertise "5,000 mg ashwagandha per serving." The math is a marketing convention, not a lie in the seller's mind, but the panel says 500 mg, so the detail page is claiming ten times the amount that is actually in the capsule. Amazon treats that as a misleading claim.

If your listing uses any raw-herb equivalency, "X:1 extract," or "equivalent to" language with a bigger number than the panel shows, fix it now. State the amount on the panel. You can still say it is a concentrated 10:1 extract; you cannot lead with the inflated number.

2. Name and form mismatches

The panel says "magnesium (as magnesium oxide)" and the bullets say "magnesium glycinate," because the formula changed in 2023 and the copy never did. Or the panel lists a proprietary blend and the bullets break out per-ingredient amounts that are not on the label at all. Both are mismatches, and both are the kind of thing a structural audit catches in seconds and a human skimming the listing misses.

3. Amounts that appear nowhere on the label

Bullets that state "2,000 IU vitamin D" when the panel says 1,000 IU, usually because the copy was cloned from a sister product or a two-capsule serving was described as one. Amazon's systems compare the numbers on your detail page against the numbers on your label images, so these get flagged even when nobody complains.

Why legacy listings are the real risk

Most deactivations under this policy are not new products slipping through. They are legacy ASINs: listings written before the current policy, edited by three different agencies, migrated through a rebrand, and never once checked line by line against the current label. The product is fine. The copy is stale. Amazon does not distinguish.

This matters for how you audit. Sorting your catalog by revenue and checking your top sellers first feels responsible, but your top sellers usually have the freshest copy. The risk concentrates in the long tail: older ASINs, variation children, and international copies of US listings.

A practical audit checklist

Work through this per ASIN, with the current label image open next to the detail page:

1. Every number on the page must be on the panel. Bullets, title, A+ content, and images. If the page says a milligram amount, find it on the Supplement Facts panel. No equivalency math.
2. Every ingredient name must match the panel's wording. Form included: "magnesium oxide" is not "magnesium glycinate," and "ashwagandha root extract" is not "ashwagandha."
3. Serving-size framing must match. If the panel amounts are per 2-capsule serving, do not describe them as per capsule.
4. Check the images, not just the text. Rendered label graphics and infographic callouts get flagged the same way body copy does. An old infographic with a superseded formula is a violation sitting in plain sight.
5. Check for disease language while you are in there. Claims enforcement travels together. A listing flagged for ingredient mismatches gets human review, and human review also catches "supports joint pain relief" style language. Our guide to structure/function claims versus disease claims covers where that line sits.
6. Confirm your documents are ready. If a listing does get deactivated, the appeal will ask for the label and usually a Certificate of Analysis. Amazon is separately rolling out third-party cGMP verification requirements, so the document request is coming either way. Here is what to keep on file.

If a listing has already been deactivated

Do not resubmit with cosmetic edits. Enforcement under this policy is content-based, so the appeal needs to show the specific mismatch is gone: corrected copy, the current label, and a short factual explanation of what changed. A rushed appeal that leaves one inflated number in A+ content burns an attempt. Our walkthrough of writing a plan of action that reinstates a listing covers the structure that works.

The cheap way to do this

Reading every bullet of every ASIN against every label is exactly the kind of work that does not get done, which is why legacy listings are the problem in the first place. VERID8 does the structural comparison automatically: it checks listing text and images against FDA, FTC, and Amazon rules, flags ingredient-claim mismatches and disease language, and hands you a compliant rewrite for each finding. You can run one listing through it free, no Amazon account connection required.

The sellers getting deactivated this year are not the ones with bad products. They are the ones who assumed old copy was safe because it had always been fine. It was fine until Amazon started checking.